Jelena Blagojevic1, G Abignano2,3, J Avouac4, L Cometi5, M Frerix6, S Bellando-Randone5, S Guiducci5, C Bruni5, D Huscher7, V K Jaeger8, V Lóránd9, B Maurer10, S Nihtyanova11, G Riemekasten12, E Siegert13, I H Tarner6, S Vettori14, U A Walker8, L Czirják9, C P Denton11, O Distler10, Y Allanore4, U Müller-Ladner6, A Moggi-Pignone15, M Matucci-Cerinic5, F Del Galdo3. 1. Department of Experimental and Clinical Medicine, Department of Geriatric Medicine, Division of Rheumatology and Scleroderma Unit AOUC, University of Florence, Florence, Italy. jelena308@hotmail.com. 2. Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy. 3. NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. 4. Department of Rheumatology, University of Paris Descartes, Paris, France. 5. Department of Experimental and Clinical Medicine, Department of Geriatric Medicine, Division of Rheumatology and Scleroderma Unit AOUC, University of Florence, Florence, Italy. 6. Department of Rheumatology and Clinical Immunology, Kerckhoff Klinik GmbH, Campus of the Justus-Liebig University Giessen, Bad Nauheim, Germany. 7. Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Berlin, Germany. 8. Department of Rheumatology, University of Basel, Basel, Switzerland. 9. Department of Rheumatology and Immunology, University of Pécs, Pecs, Hungary. 10. Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland. 11. Department of Rheumatology, University College London, Royal Free Hospital, London, UK. 12. Clinic of Rheumatology and Clinical Immunology, University of Lübeck, Lubeck, Germany. 13. Department of Rheumatology and Clinical Immunology, Charité - Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, and Berlin Institute of Health, Berlin, Germany. 14. Rheumatology Section, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. 15. Department of Experimental and Clinical Medicine, Department of Emergency, Division of Medicine IV AOUC, University of Florence, Florence, Italy.
Abstract
INTRODUCTION: DeSScipher is the first European multicentre study on management of systemic sclerosis (SSc), and its observational trial 1 (OT1) evaluated the efficacy of different drugs for digital ulcer (DU) prevention and healing. The aim of this study was to assess current use of vasoactive/vasodilating agents for SSc-related DU in the expert centres by analysing the baseline data of the DeSScipher OT1. METHOD: Baseline characteristics of patients enrolled in the OT1 and data regarding DU were analysed. RESULTS: The most commonly used drugs, in both patients with and without DU, were calcium channel blockers (CCBs) (71.6%), followed by intravenous iloprost (20.8%), endothelin receptor antagonists (ERAs) (20.4%) and phosphodiesterase 5 (PDE-5) inhibitors (16.5%). Of patients, 32.6% with DU and 12.8% without DU received two drugs (p < 0.001), while 11.5% with DU and 1.9% without DU were treated with a combination of three or more agents (p < 0.001). Sixty-five percent of the patients with recurrent DU were treated with bosentan and/or sildenafil. However, 64 out of 277 patients with current DU (23.1%) and 101 (23.6%) patients with recurrent DU were on CCBs alone. CONCLUSIONS: Our study shows that CCBs are still the most commonly used agents for DU management in SSc. The proportion of patients on combination therapy was low, even in patients with recurrent DU: almost one out of four patients with current and recurrent DU was on CCBs alone. Prospective analysis is planned to investigate the efficacy of different drugs/drug combinations on DU healing and prevention. Key Points • The analysis of DeSScipher, the first European multicentre study on management of SSc, has shown that the most commonly used vasoactive/vasodilating drugs for DU were CCBs, followed by intravenous Iloprost, ERAs and PDE-5 inhibitors. • More than half of the patients with recurrent DU received bosentan and/or sildenafil. • However, the proportion of patients on combination therapy of more than one vasoactive/vasodilating drug was low and almost one out of four patients with current and recurrent DU was on CCBs alone.
INTRODUCTION: DeSScipher is the first European multicentre study on management of systemic sclerosis (SSc), and its observational trial 1 (OT1) evaluated the efficacy of different drugs for digital ulcer (DU) prevention and healing. The aim of this study was to assess current use of vasoactive/vasodilating agents for SSc-related DU in the expert centres by analysing the baseline data of the DeSScipher OT1. METHOD: Baseline characteristics of patients enrolled in the OT1 and data regarding DU were analysed. RESULTS: The most commonly used drugs, in both patients with and without DU, were calcium channel blockers (CCBs) (71.6%), followed by intravenous iloprost (20.8%), endothelin receptor antagonists (ERAs) (20.4%) and phosphodiesterase 5 (PDE-5) inhibitors (16.5%). Of patients, 32.6% with DU and 12.8% without DU received two drugs (p < 0.001), while 11.5% with DU and 1.9% without DU were treated with a combination of three or more agents (p < 0.001). Sixty-five percent of the patients with recurrent DU were treated with bosentan and/or sildenafil. However, 64 out of 277 patients with current DU (23.1%) and 101 (23.6%) patients with recurrent DU were on CCBs alone. CONCLUSIONS: Our study shows that CCBs are still the most commonly used agents for DU management in SSc. The proportion of patients on combination therapy was low, even in patients with recurrent DU: almost one out of four patients with current and recurrent DU was on CCBs alone. Prospective analysis is planned to investigate the efficacy of different drugs/drug combinations on DU healing and prevention. Key Points • The analysis of DeSScipher, the first European multicentre study on management of SSc, has shown that the most commonly used vasoactive/vasodilating drugs for DU were CCBs, followed by intravenous Iloprost, ERAs and PDE-5 inhibitors. • More than half of the patients with recurrent DU received bosentan and/or sildenafil. • However, the proportion of patients on combination therapy of more than one vasoactive/vasodilating drug was low and almost one out of four patients with current and recurrent DU was on CCBs alone.
Entities:
Keywords:
Digital ulcer; Management; Systemic sclerosis
Authors: Carina Mihai; Robert Landewé; Désirée van der Heijde; Ulrich A Walker; Paul I Constantin; Ana Maria Gherghe; Ruxandra Ionescu; Simona Rednic; Yannick Allanore; Jérôme Avouac; László Czirják; Eric Hachulla; Gabriela Riemekasten; Franco Cozzi; Paolo Airò; Maurizio Cutolo; Ulf Mueller-Ladner; Marco Matucci-Cerinic Journal: Ann Rheum Dis Date: 2015-02-16 Impact factor: 19.103
Authors: Veronika K Jaeger; Gabriele Valentini; Eric Hachulla; Franco Cozzi; Oliver Distler; Paolo Airó; Laszlo Czirják; Yannick Allanore; Elise Siegert; Edoardo Rosato; Marco Matucci-Cerinic; Cristian Caimmi; Jörg Henes; Patricia E Carreira; Vanessa Smith; Francesco Del Galdo; Christopher P Denton; Susanne Ullman; Ellen De Langhe; Valeria Riccieri; Juan J Alegre-Sancho; Simona Rednic; Ulf Müller-Ladner; Ulrich A Walker Journal: Arthritis Rheumatol Date: 2018-09-24 Impact factor: 10.995
Authors: U A Walker; A Tyndall; L Czirják; C Denton; D Farge-Bancel; O Kowal-Bielecka; U Müller-Ladner; C Bocelli-Tyndall; M Matucci-Cerinic Journal: Ann Rheum Dis Date: 2007-01-18 Impact factor: 19.103
Authors: Y A Suliman; C Bruni; S R Johnson; E Praino; M Alemam; N Borazan; L Cometi; B Meyers; D Khanna; Y Allanore; M Baron; T Krieg; A Herrick; A Afonso; O Distler; S Kafaja; C P Denton; M Matucci-Cerinic; D E Furst Journal: J Scleroderma Relat Disord Date: 2017-05-19
Authors: Christopher P Denton; Thomas Krieg; Loic Guillevin; Barbara Schwierin; Daniel Rosenberg; Mariabeth Silkey; Maurice Zultak; Marco Matucci-Cerinic Journal: Ann Rheum Dis Date: 2012-01-12 Impact factor: 19.103
Authors: Yannick Allanore; Christopher P Denton; Thomas Krieg; Peter Cornelisse; Daniel Rosenberg; Barbara Schwierin; Marco Matucci-Cerinic Journal: Ann Rheum Dis Date: 2016-06-27 Impact factor: 19.103
Authors: S Panopoulos; Κ Chatzidionysiou; M G Tektonidou; V K Bournia; A A Drosos; Stamatis-Nick C Liossis; T Dimitroulas; L Sakkas; D Boumpas; P V Voulgari; D Daoussis; K Thomas; G Georgiopoulos; G Vosvotekas; Α Garyfallos; P Sidiropoulos; G Bertsias; D Vassilopoulos; P P Sfikakis Journal: Arthritis Res Ther Date: 2020-03-23 Impact factor: 5.156